Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost
Carl Erb,1 Ingeborg Stalmans,2 Milko Iliev,3 Francisco José Muñoz-Negrete4 1Eye Clinic Wittenbergplatz, Berlin, Germany; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland; 4S...
Guardado en:
Autores principales: | , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/204c16e73afe4faf972faca88aaa6031 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:204c16e73afe4faf972faca88aaa6031 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:204c16e73afe4faf972faca88aaa60312021-12-02T13:33:13ZReal-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost1177-5483https://doaj.org/article/204c16e73afe4faf972faca88aaa60312021-03-01T00:00:00Zhttps://www.dovepress.com/real-world-study-on-patient-satisfaction-and-tolerability-after-switch-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Carl Erb,1 Ingeborg Stalmans,2 Milko Iliev,3 Francisco José Muñoz-Negrete4 1Eye Clinic Wittenbergplatz, Berlin, Germany; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland; 4Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaCorrespondence: Francisco José Muñoz-NegreteServicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaTel +34 913 36 80 00Email franciscojmunoz@telefonica.netPurpose: Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who had received preservative-free latanoprost (PFL) for at least 3 months.Patients and Methods: A total of 1872 patients from 6 European countries, treated with PFL for at least 3 months, were included in this survey. Prior to PFL treatment, patients were to be treatment naïve or currently treated for their glaucoma. During a single routine consultation, patients completed a questionnaire concerning global satisfaction and satisfaction based on tolerability.Results: In total, 76.2% had been previously treated; 69.4% had received preserved and 6.8% preservative-free (PF) topical treatment. After 3 months of PFL treatment, a large majority of patients (95.3%) were satisfied or very satisfied with their PFL treatment and were, overall, significantly (p< 0.0001) more satisfied with PFL than with their previous treatment; 4.2% were either unsatisfied or very unsatisfied. Overall, 97.3% of originally treatment-naïve patients were satisfied (50.1%) or very satisfied (47.2%) with their PFL. Ocular surface disease was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Patient satisfaction with PFL was very high. Conclusion: PFL may be considered a valuable first-choice treatment in glaucoma patients.Keywords: glaucoma, prostaglandin, preservative-free latanoprost, patient satisfaction, tolerability, tear substitutes, intra-ocular pressure, ocular surface disease, conjunctival hyperaemiaErb CStalmans IIliev MMuñoz-Negrete FJDove Medical Pressarticleglaucomaprostaglandinpreservative-free latanoprostpatient satisfactiontolerabilitytear substitutesintra-ocular pressureocular surface diseaseconjunctival hyperaemiaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 931-938 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
glaucoma prostaglandin preservative-free latanoprost patient satisfaction tolerability tear substitutes intra-ocular pressure ocular surface disease conjunctival hyperaemia Ophthalmology RE1-994 |
spellingShingle |
glaucoma prostaglandin preservative-free latanoprost patient satisfaction tolerability tear substitutes intra-ocular pressure ocular surface disease conjunctival hyperaemia Ophthalmology RE1-994 Erb C Stalmans I Iliev M Muñoz-Negrete FJ Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost |
description |
Carl Erb,1 Ingeborg Stalmans,2 Milko Iliev,3 Francisco José Muñoz-Negrete4 1Eye Clinic Wittenbergplatz, Berlin, Germany; 2Department of Ophthalmology, University Hospitals Leuven, Leuven, Belgium; 3Ophthalmology Department, University of Bern, Inselspital, Bern, Switzerland; 4Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaCorrespondence: Francisco José Muñoz-NegreteServicio de Oftalmología, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, IRYCIS, Madrid, EspañaTel +34 913 36 80 00Email franciscojmunoz@telefonica.netPurpose: Patient satisfaction is important in the treatment of glaucoma. Suboptimal compliance and impaired long-term outcome are a likely result of poor tolerability. The present multicentre, international, transverse, epidemiological survey was conducted to assess the satisfaction of patients who had received preservative-free latanoprost (PFL) for at least 3 months.Patients and Methods: A total of 1872 patients from 6 European countries, treated with PFL for at least 3 months, were included in this survey. Prior to PFL treatment, patients were to be treatment naïve or currently treated for their glaucoma. During a single routine consultation, patients completed a questionnaire concerning global satisfaction and satisfaction based on tolerability.Results: In total, 76.2% had been previously treated; 69.4% had received preserved and 6.8% preservative-free (PF) topical treatment. After 3 months of PFL treatment, a large majority of patients (95.3%) were satisfied or very satisfied with their PFL treatment and were, overall, significantly (p< 0.0001) more satisfied with PFL than with their previous treatment; 4.2% were either unsatisfied or very unsatisfied. Overall, 97.3% of originally treatment-naïve patients were satisfied (50.1%) or very satisfied (47.2%) with their PFL. Ocular surface disease was diagnosed in 9.2% of patients (n=173) and was mainly mild (76.9%). Patient satisfaction with PFL was very high. Conclusion: PFL may be considered a valuable first-choice treatment in glaucoma patients.Keywords: glaucoma, prostaglandin, preservative-free latanoprost, patient satisfaction, tolerability, tear substitutes, intra-ocular pressure, ocular surface disease, conjunctival hyperaemia |
format |
article |
author |
Erb C Stalmans I Iliev M Muñoz-Negrete FJ |
author_facet |
Erb C Stalmans I Iliev M Muñoz-Negrete FJ |
author_sort |
Erb C |
title |
Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost |
title_short |
Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost |
title_full |
Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost |
title_fullStr |
Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost |
title_full_unstemmed |
Real-World Study on Patient Satisfaction and Tolerability After Switching to Preservative-Free Latanoprost |
title_sort |
real-world study on patient satisfaction and tolerability after switching to preservative-free latanoprost |
publisher |
Dove Medical Press |
publishDate |
2021 |
url |
https://doaj.org/article/204c16e73afe4faf972faca88aaa6031 |
work_keys_str_mv |
AT erbc realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost AT stalmansi realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost AT ilievm realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost AT munoznegretefj realworldstudyonpatientsatisfactionandtolerabilityafterswitchingtopreservativefreelatanoprost |
_version_ |
1718392841220128768 |